EPS: As of FY2025 Q2, the actual value is USD -0.54.EBIT: As of FY2025 Q2, the actual value is USD -2.265 M.<h3>Financial Highlights</h3><ul><li>Net Loss: Kiora Pharmaceuticals reported a net loss of $2.2 million for the second quarter of 2025, consistent with the net loss of $2.2 million in the second quarter of 2024.</li><li>Research and Development (R&amp;D) Expenses: R&amp;D expenses for the second quarter of 2025 were $2.6 million, before recognizing $1.7 million in reimbursable expenses from Théa. This is an increase from $2.0 million in the second quarter of 2024, with $1.1 million in offsetting reimbursable expenses from Théa.</li><li>General and Administrative (G&amp;A) Expenses: G&amp;A expenses were $1.4 million for the second quarter of 2025, down from $1.5 million in the second quarter of 2024.</li><li>Cash and Cash Equivalents: The company ended the quarter with $20.7 million in cash, cash equivalents, and short-term investments.</li><li>Collaboration Receivables: Kiora recorded $1.2 million in collaboration receivables from Théa for reimbursable R&amp;D expenses and $1.25 million in collaboration receivables from Senju related to the option fee.</li><li>Deferred Revenue: The company recorded deferred revenue of $1.25 million related to a non-refundable option fee from Senju.</li></ul><h3>Outlook / Guidance</h3>Kiora Pharmaceuticals anticipates maintaining its cash runway into late 2027, which extends beyond the anticipated data readouts for the KLARITY and ABACUS-2 trials. The company is actively recruiting for its Phase 2 clinical trials, with strategic partnerships expected to enhance global commercialization efforts. The potential deal with Senju could be valued at up to $110 million plus royalties, contingent on the exercise of the option agreement.

Kiora Pharmaceuticals | 8-K: FY2025 Q2 EPS: USD -0.54